Table 6.

Respiratory parameters at baseline and change at 2 hours post-baseline

	Placebo		Regadenoson		P valuea
	n	Mean ± SD	n	Mean ± SD
Asthma stratum
FEV1 (L)
Baseline	176	2.41 ± 0.689	356	2.35 ± 0.623
Change at Hour 2	174	−0.05 ± 0.160	351	−0.01 ± 0.129	.0029**
FVC (L)
Baseline	176	3.22 ± 0.883	356	3.16 ± 0.829
Change at Hour 2	174	−0.06 ± 0.208	351	−0.03 ± 0.168	.0789
FEV1/FVC ratio
Baseline	176	74.88 ± 7.510	356	74.59 ± 7.084
Change at Hour 2	174	0.16 ± 3.329	351	0.52 ± 2.562	.2087
COPD stratum
FEV1 (L)
Baseline	151	1.70 ± 0.630	316	1.70 ± 0.655
Change at Hour 2	147	−0.01 ± 0.152	313	−0.00 ± 0.159	.6189
FVC (L)
Baseline	151	2.75 ± 0.833	316	2.83 ± 0.899
Change at Hour 2	147	−0.04 ± 0.230	313	0.00 ± 0.239	.0258*
FEV1/FVC ratio
Baseline	151	61.95 ± 12.684	316	60.00 ± 13.191
Change at Hour 2	147	0.31 ± 3.177	313	−0.30 ± 3.571	.0289*

COPD, Chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV ₁, forced expiratory volume in 1 second; SD, standard deviation.

*^,**Statistical significance at level of P = .05 and P = .01, respectively.

^a F test from ANCOVA with treatment and investigator site as main effects and baseline value as a covariate in the model.